Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Repligen Corporation    RGEN

REPLIGEN CORPORATION

(RGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
187.29(c) 193.51(c) 185.87(c) 179.15(c) 181.43 Last
397 160 587 551 423 744 480 473 259 727 Volume
+0.99% +3.32% -3.95% -3.62% +1.27% Change
More quotes
Financials (USD)
Sales 2020 351 M - -
Net income 2020 49,6 M - -
Net cash position 2020 224 M - -
P/E ratio 2020 195x
Yield 2020 -
Sales 2021 452 M - -
Net income 2021 65,2 M - -
Net cash position 2021 314 M - -
P/E ratio 2021 154x
Yield 2021 -
Capitalization 9 427 M 9 427 M -
EV / Sales 2020 26,2x
EV / Sales 2021 20,2x
Nbr of Employees -
Free-Float 92,7%
More Financials
Company
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used... 
More about the company
Notations Surperformance© of Repligen Corporation
Trading Rating : Investor Rating :
More Ratings
All news about REPLIGEN CORPORATION
11/05REPLIGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
11/05REPLIGEN : 3Q Earnings Snapshot
AQ
11/05REPLIGEN CORP : Results of Operations and Financial Condition, Financial Stateme..
AQ
11/05REPLIGEN : Reports Third Quarter 2020 Financial Results and Updates Full Year 20..
AQ
11/05Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2..
GL
10/27REPLIGEN CORP : Regulation FD Disclosure, Other Events, Financial Statements and..
AQ
10/27REPLIGEN CORPORATION : Announces Agreement to Acquire Bioprocess Systems Innovat..
AQ
10/27Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innova..
GL
10/22REPLIGEN : to Report Third Quarter 2020 Financial Results
AQ
10/22Repligen to Report Third Quarter 2020 Financial Results
GL
10/02REPLIGEN : and Navigo Proteins Announce Achievement of Key Milestone in Developi..
AQ
10/01REPLIGEN : and Navigo Proteins Announce Achievement of Key Milestone in Developi..
AQ
10/01Repligen and Navigo Proteins Announce Achievement of Key Milestone in Develop..
GL
07/30REPLIGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
07/30REPLIGEN : 2Q Earnings Snapshot
AQ
More news
News in other languages on REPLIGEN CORPORATION
2014REPLIGEN CORPORATION : publication des résultats trimestriels
2013REPLIGEN CORPORATION : publication des résultats trimestriels
More news
Stock Trading Strategies
REPLIGEN CORPORATION - 11/13
Increase of volatility
BUY
More Stock Trading Analysis
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | RGEN | US7599161095 | MarketScreener
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 217,71 $
Last Close Price 181,43 $
Spread / Highest target 32,8%
Spread / Average Target 20,0%
Spread / Lowest Target -4,10%
EPS Revisions
Managers
NameTitle
Tony J. Hunt President, Chief Executive Officer & Director
Karen A. Dawes Chairman
Steve Curran Vice President-Global Operations
Jon K. Snodgres Secretary, Chief Financial & Accounting Officer
Ralf Kuriyel Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
REPLIGEN CORPORATION100.94%9 427
ABBOTT LABORATORIES23.89%190 724
MEDTRONIC PLC0.54%152 963
BECTON, DICKINSON AND COMPANY-15.69%66 464
HOYA CORPORATION29.62%46 912
BAXTER INTERNATIONAL INC.-9.08%38 838